Pacira BioSciences, Inc.PCRXNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P31
Within normal range
vs 5Y Ago
-1.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -28.18% |
| Q3 2025 | 406.44% |
| Q2 2025 | -66.12% |
| Q1 2025 | 7.02% |
| Q4 2024 | -38.55% |
| Q3 2024 | 1.28% |
| Q2 2024 | 8.42% |
| Q1 2024 | 3.19% |
| Q4 2023 | 7.08% |
| Q3 2023 | 2.16% |
| Q2 2023 | 127.41% |
| Q1 2023 | -54.50% |
| Q4 2022 | -1.45% |
| Q3 2022 | 43.11% |
| Q2 2022 | -3.15% |
| Q1 2022 | 32.57% |
| Q4 2021 | -61.49% |
| Q3 2021 | 100.06% |
| Q2 2021 | 149.43% |
| Q1 2021 | -74.11% |
| Q4 2020 | 17.31% |
| Q3 2020 | 354.61% |
| Q2 2020 | -351.68% |
| Q1 2020 | -76.03% |
| Q4 2019 | 41.14% |
| Q3 2019 | -19.37% |
| Q2 2019 | 550.56% |
| Q1 2019 | -83.51% |
| Q4 2018 | 27.61% |
| Q3 2018 | 21.29% |
| Q2 2018 | 609.85% |
| Q1 2018 | -115.88% |
| Q4 2017 | 702.96% |
| Q3 2017 | -176.81% |
| Q2 2017 | 60833.33% |
| Q1 2017 | -99.97% |
| Q4 2016 | 48.49% |
| Q3 2016 | 54.94% |
| Q2 2016 | 341.62% |
| Q1 2016 | -118.32% |